#SARS-CoV-2

Updated boosters could go to the “worried well” who have good insurance rather than to those at highest risk.

Higher levels of viral antigens in the blood correlated with more severe disease.

Updated Pfizer-BioNTech and Moderna bivalent boosters contain spike proteins from the original and BA.4 and BA.5 omicron variants.

Whether omicron coronavirus variants cause long COVID symptoms as often—and as severe—as previous variants is a matter of heated study.

An experimental vaccine produced an immune response to a range of different coronaviruses in mice and monkeys, including SARS-CoV-2.

The engineered protein vaccine was highly effective in a clinical trial but faced a long delay for authorization.

The update aims to help the public better protect themselves and understand their risk.

Using wastewater to track the emergence of new variants of concern could be faster and less expensive than clinical testing.

New studies offer evidence that an unexpected virus plays a role—but it needs a helper.

Antibody levels decrease substantially within three months after a booster, according to new clinical trial data.

People of European or African ancestry who were hospitalized for COVID-19 are more likely to carry particular genetic variants.

Findings from small NIH study could provide insight into long-term neurological symptoms of COVID-19.

Prolonged inflammation after SARS-CoV-2 infection caused permanent organ damage, affected the brain and correlated with behavioral changes.

Two drugs widely used to treat certain autoimmune diseases substantially improved clinical status and reduced deaths.

After a long wait, the FDA authorizes Pfizer and Moderna vaccines for children as young as 6 months old.

The virus can be transmitted via respiratory droplets at close range, but it does not spread through the air over longer distances.